Source: American Academy of Ophthalmology
Wednesday, October 03, 2007
Schwartz et al. recently demonstrated that a T cell–based vaccination, using synthetic antigens (glatiramer acetate, also known as Copolymer-1 or Cop-1) that cross-react weakly with retinal and optic nerve antigens, reduces the loss of retinal ganglion cells in a rat model of chronic glaucoma.1 This vaccine not only boosted the T-cell response, it did it without causing an autoimmune disease.
advertisement
You do not have JavaScript enabled or are using an older version of
Adobe Flash. You can update your version of Adobe Flash here.
The vaccination did not prevent glaucoma, but it slowed its progression by controlling the local extracellular environment of the nerve and retina. In other words, vaccination created an environment more conducive to neuronal survival and helped the retinal ganglion cells withstand the stress.
Human studies are underway. If it is successful, this innovative approach would complement conventional glaucoma treatment.
REFEREENCE
1. Schwartz M. Modulating the immune system: a vaccine for glaucoma? Can J Ophthalmol. 2007;42(3):439-441.